TrialDigestive diseases (Basel, Switzerland)2021

Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.

Naohisa Wada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.